Literature DB >> 15039147

Assessment of the function of the betaC-subunit of activin in cultured hepatocytes.

Wataru Wada1, Akito Maeshima, You-Qing Zhang, Yoshihisa Hasegawa, Hiroyuki Kuwano, Itaru Kojima.   

Abstract

We assessed the function of the beta(C)-subunit of activin in hepatocytes. We studied the effect of conditioned medium of Chinese hamster ovary (CHO) cell line stably expressing the beta(C) gene (CHO-beta(C)) on growth of AML12 hepatocytes. We also examined the effect of recombinant activin C and transfection of the beta(C) gene by using adenovirus vector. CHO-beta(C) secreted activin C, a homodimer of the beta(C), as well as precursors of the beta(C). The conditioned medium of CHO-beta(C) increased both [(3)H]thymidine incorporation and the cell number in AML12 cells. It also supported survival of AML12 cells in a serum-free condition. Recombinant human activin C also increased both [(3)H]thymidine incorporation and the number of AML12 cells. Transfection of AML12 cells with the beta(C)-subunit led to the stimulation of [(3)H]thymidine incorporation. Analysis of the conditioned medium revealed that the beta(C)-subunit formed a heterodimer with the endogenous beta(A), the formation of which was dependent on the amount of beta(C) expressed. Recombinant activin C did not affect the binding of (125)I-activin A to its receptor or follistatin. These results indicate that activin C stimulates growth of AML12 cells. The beta(C)-subunit modifies the function of the beta(A)-subunit by multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15039147     DOI: 10.1152/ajpendo.00390.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  8 in total

1.  Activins and follistatins: Emerging roles in liver physiology and cancer.

Authors:  Emanuel Kreidl; Deniz Oztürk; Thomas Metzner; Walter Berger; Michael Grusch
Journal:  World J Hepatol       Date:  2009-10-31

2.  Rat activin-betaE mRNA expression during development and in acute and chronic liver injury.

Authors:  Elspeth J Gold; Marcel A Monaghan; Jean S Fleming
Journal:  J Mol Genet Med       Date:  2006-04-12

3.  Transforming growth factor beta family expression at the bovine feto-maternal interface.

Authors:  Kumiko Sugawara; Keiichiro Kizaki; Chandana B Herath; Yoshihisa Hasegawa; Kazuyoshi Hashizume
Journal:  Reprod Biol Endocrinol       Date:  2010-10-15       Impact factor: 5.211

Review 4.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

5.  Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo.

Authors:  Elspeth Gold; Niti Jetly; Moira K O'Bryan; Sarah Meachem; Deepa Srinivasan; Supreeti Behuria; L Gabriel Sanchez-Partida; Teresa Woodruff; Shelley Hedwards; Hong Wang; Helen McDougall; Victoria Casey; Birunthi Niranjan; Shane Patella; Gail Risbridger
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

6.  Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1.

Authors:  Hongwei Yuan; John Y-J Shyy; Manuela Martins-Green
Journal:  J Hepatol       Date:  2009-05-18       Impact factor: 25.083

7.  Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?

Authors:  K Frost; K Seir; A Lackner; M Grusch; B Grasl-Kraupp; R Schulte-Hermann; C Rodgarkia-Dara
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

8.  Differential cerebral cortex transcriptomes of baboon neonates consuming moderate and high docosahexaenoic acid formulas.

Authors:  Kumar S D Kothapalli; Joshua C Anthony; Bruce S Pan; Andrea T Hsieh; Peter W Nathanielsz; J Thomas Brenna
Journal:  PLoS One       Date:  2007-04-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.